Obesity drugs, a golden opportunity?

GLP-1 drugs will not only reshape obesity treatment, but also generate exceptional investment opportunities.

The fight against obesity is entering a promising new phase thanks to GLP-1 drugs, such as Wegovy and Saxenda, which are transforming the weight loss market. As the number of people suffering from obesity continues to rise around the world, these drugs not only bring hope to millions, but also represent a booming investment opportunity.

Obesity among adults has more than doubled since 1990 worldwide. With more than 40%, the United States had one of the highest concentrations in the world of people with a body mass index (BMI) greater than 30 in 2022. Thirty years ago, this proportion was slightly less than 20%. The number of obese people worldwide is expected to increase further, from 980 million to nearly 2 billion between 2022 and 2035.

Revolution in treatment: GLP-1 drugs

Originally developed to treat diabetes, GLP-1 drugs are now on the front lines in the fight against obesity. Not only do they help with weight loss, they can also reduce the risk of associated diseases like diabetes and stroke. The market leaders are Eli Lilly and Novo Nordisk, whose drugs such as Wegovy, Saxenda and the newly released Zepbound have shown impressive results.

Investment Landscape and Market Dynamics

The economic potential of obesity drugs is enormous, with a market expected to reach $100 billion by 2030. Despite their high effectiveness, current demand far exceeds supply, leading to shortages and a surge in sales on black market. This imbalance presents a clear signal to investors about the urgency and profitability of expanding production capacity.

Financial data and future projections

Eli Lilly and Novo Nordisk have already invested heavily, planning capital expenditures of approximately $30 billion between now and 2026 to grow their production capabilities. However, these massive investments may not be enough to fully meet needs, which suggests high and sustainable returns for early investors. The stock performance of these companies has reflected this growth potential, with significant gains since the introduction of these drugs.

To weigh the pros and cons

Although the outlook is promising, investors should consider potential risks. Regulatory changes, market saturation and the development of new treatments could impact future returns. Additionally, the ethical and health implications of widespread use of these drugs could lead to stricter regulations.

The role of new entrants

While large pharmaceutical companies, such as Eli Lilly and Novo Nordisk, currently dominate the global obesity market, other companies have the opportunity to innovate and capture niche markets. This could generate attractive returns for investors willing to bet on these emerging players.

As the fight against obesity intensifies, the economic implications are far-reaching. Investors looking for the next big thing in healthcare might find it in obesity drugs, which promise not only to improve the lives of millions of people but also deliver substantial economic returns . Favoring a strategic investment, the financial benefits could be as important as the health benefits.

-

-

PREV “It generates toxic substances, some of which are known to cause cancer”
NEXT Here is the method to fall asleep quickly and have a great night